Company Shares of Incyte Corporation (NASDAQ:INCY) Rally 5.45%

Incyte Corporation (NASDAQ:INCY) : Traders are bullish on Incyte Corporation (NASDAQ:INCY) as it has outperformed the S&P 500 by a wide margin of 4.89% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 4.12%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 5.45% in the last 1 week, and is up 6.58% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The company shares have dropped -24.16% from its 1 Year high price. On Sep 16, 2015, the shares registered one year high at $133.62 and the one year low was seen on Feb 11, 2016. The 50-Day Moving Average price is $81.01 and the 200 Day Moving Average price is recorded at $78.05.

The stock has recorded a 20-day Moving Average of 8.05% and the 50-Day Moving Average is 9.62%.


Incyte Corporation (NASDAQ:INCY): stock turned positive on Friday. Though the stock opened at $83.29, the bulls momentum made the stock top out at $85.88 level for the day. The stock recorded a low of $82.965 and closed the trading day at $85.7, in the green by 2.60%. The total traded volume for the day was 905,905. The stock had closed at $83.53 in the previous days trading.

In an insider trading activity, Swain Paula J, officer (EVP, Human Resources) of Incyte Corp, unloaded 13,531 shares at an average price of $76.96 on January 15, 2016. The total amount of the transaction was worth $1,041,346, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.

Incyte Corporation is a biopharmaceutical company focused on the discovery development and commercialization of small molecule drugs to treat serious unmet medical needs. The Companys compound JAKAFI (ruxolitinib) also known as INCB18424 and INC424 is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or highrisk myelofibrosis (MF) including primary MF postpolycythemia vera MF and postessential thrombocythemia MF. The Company has a second oral JAK1 and JAK2 inhibitor LY3009104 (INCB28050) , which is subject to a collaboration agreement with Eli Lilly and Company in , which Lilly received development and commercialization rights f

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.